B 001

Drug Profile

B 001

Alternative Names: B001

Latest Information Update: 11 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shanghai Pharmaceuticals Holding
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 06 Nov 2017 Preclinical trials in Haematological malignancies in China (IV) before November 2017 (NCT03332121)
  • 06 Nov 2017 Shanghai Pharmaceuticals Holding plans a phase Ia trial for B-cell lymphoma and Chronic lymphocytic leukaemia (Second-line therapy or greater) in (China) (NCT03332121)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top